Myasthenia gravis: Do the subtypes matter?

作者
Jagarlapudi M. K. Murthy
出处
期刊:Annals of Indian Academy of Neurology [Medknow]
卷期号:23 (1): 2-2 被引量:9
标识
DOI:10.4103/aian.aian_595_19
摘要

Acquired myasthenia gravis (MG) is a group of neuromuscular junction (NMJ) disorders caused by autoantibodies against components of postsynaptic muscle endplate. Autoantibodies target the acetylcholine receptor (AChR), muscle-specific kinase (MuSK), low-density lipoprotein receptor-related protein 4 (LRP4) and agrin. Clinically, MG is characterised by fluctuant muscle weakness.[1] MG is classified into subtypes based on serum antibodies and clinical features. Identification of the specific subtype dictates the therapeutic approach and also prognosis.[12] Clinical subtypes include ocular MG, early-onset generalised MG and late-onset MG. The subtypes by antibodies include MG with AChR antibodies, MG with anti-MuSK antibodies, MG with anti-LRP4 antibodies, seronegative myasthenia and myasthenia with coexisting autoimmune diseases.[12] The other subtype is adult-onset MG with thymoma with titin and ryanodine receptor antibodies.[3] The relative prevalence of subtypes by antibodies is: MG with AChR antibodies 80%, MG with MuSK antibodies 4%, MG with LRP4 antibodies 2% and seronegative myasthenia.[1] In this issue of Annals of India Academy of Neurology, Samal and colleagues compared the demographic and clinical characteristics, treatment response, and outcome of MG with MuSK antibodies, MG with AChR antibodies and seronegative MG.[4] They did not find any difference among all the three subtypes in all the parameters studied including long-term prognosis and quality of life. The authors concluded that clinical features and response to therapy in addition to antibody status must be considered before planning a therapy. These observations are at variance from the published studies. The major limitations of the study are retrospective nature of the study, small sample size in the MuSK positive and seronegative groups and different treatment protocols. There are distinct differences between late-onset MG with AChR antibodies and MG with MuSK antibodies. MuSK antibodies are mainly IgG4, unlike the IgG1 and IgG3 anti-AChR antibodies, and are not complement activating.[5] MG with MuSK antibodies is seen predominantly in females, commonly has atypical clinical features such as the selective facial, bulbar, neck, and respiratory muscle weakness and marked muscle atrophy, occasionally with relative sparing of ocular muscles.[67] Respiratory crises are more common. Weakness can involve muscles that are not usually symptomatic in MG such as paraspinal and upper oesophageal muscles.[8] Anticholinesterase agents are less effective and induce frequent side effects.[9] Thymus histology is usually normal.[9] MG with MuSK antibodies has lower response with immunosuppressive treatment, and rituximab has a favourable response.[1] Thymectomy may not be associated with clinical improvement in MG with MuSK antibodies.[1011] Accumulating evidence suggests that clinical MG subtypes might respond differently to treatments. However, treatment is far from antibody specific. The future research approach should be towards an individually adapted treatment based on biomarker (autoantibody) assessment and monitoring.[1] Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
所所的应助被Czz采纳,获得10
1秒前
zz完成签到,获得积分10
1秒前
1秒前
风趣笙完成签到,获得积分10
2秒前
斯文败类的应助被撝谦采纳,获得10
2秒前
科研通AI65的应助被青年才俊采纳,获得10
2秒前
辞旧完成签到,获得积分10
3秒前
伶俐的念寒完成签到,获得积分10
3秒前
慕青的应助被esdeath采纳,获得10
3秒前
赘婿的应助被六层楼采纳,获得10
3秒前
JIA完成签到,获得积分10
4秒前
5秒前
huihui发布了新的文献求助10
6秒前
绝世完成签到,获得积分10
6秒前
6秒前
qq发布了新的文献求助10
6秒前
陶万军完成签到 ,获得积分10
6秒前
7秒前
Nole的应助被李麟采纳,获得10
8秒前
华哥完成签到,获得积分10
8秒前
9秒前
王宇洁完成签到,获得积分20
9秒前
汉堡包的应助被小汤不圆采纳,获得10
9秒前
稳重的傲芙完成签到,获得积分10
9秒前
9秒前
10秒前
10秒前
11秒前
11秒前
郑睿涛发布了新的文献求助10
12秒前
汉堡包的应助被elysia采纳,获得10
12秒前
13秒前
QiWangzhi完成签到,获得积分10
13秒前
LY关闭了LY的文献求助
13秒前
14秒前
orixero的应助被坦率的凉面采纳,获得10
14秒前
沐沐发布了新的文献求助10
15秒前
陈琛琛发布了新的文献求助30
15秒前
背后的胡萝卜完成签到,获得积分10
15秒前
泡泡发布了新的文献求助10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183739
求助须知:如何正确求助?哪些是违规求助? 9572996
关于积分的说明 21828615
捐赠科研通 7780904
什么是DOI,文献DOI怎么找? 3434101
关于科研通互助平台的介绍 2558294
邀请新用户注册赠送积分活动 2480564